Pre-earnings options volume in Summit Therapeutics (SMMT) is normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a move near 7.3%, or $1.59, after results are released. Median move over the past eight quarters is 13.8%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics put volume heavy and directionally bearish
- Summit partner selection for ASCO plenary signals strong OS, says Leerink
- Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim
- Biotech Alert: Searches spiking for these stocks today
- Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit